Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms Grant, S., Sullivan, D., Roodman, D., Stuart, R. K., Perkins, E., Kolla, S., Rarnakrishnan, V., Wright, J., Colevas, A., Tombes, M. B., Roberts, J. D. AMER SOC HEMATOLOGY. 2008: 558
View details for Web of Science ID 000262104701794